Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
encapsulated fecal microbiota transplantation
- Development stage
- Unknown
- Lead developer
- Hulan (Hangzhou) Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Encapsulated fecal microbiota transplantation (cFMT) is a therapeutic approach involving the oral administration of healthy donor fecal matter contained within acid-resistant or enteric-coated capsules. This method is designed to restore a healthy gut microbiome in patients suffering from dysbiosis-related conditions, such as hepatic encephalopathy or recurrent *Clostridioides difficile* infection, without the need for invasive delivery procedures like colonoscopy or nasoduodenal tubes. In the context of cirrhosis-related hepatic encephalopathy, cFMT aims to reduce ammonia-producing bacterial taxa and improve intestinal barrier integrity, thereby preventing the recurrence of neuropsychiatric symptoms. Clinical trials, such as those conducted at Hulan (Hangzhou) Hospital, investigate optimal dosing intervals to maintain remission in patients previously treated with standard therapies like rifaximin.
- Other names
- oral fecal microbiota transplantationcapsulized fecal microbiota transplantationfecal microbiota transplantation capsules
Beyond the preview
Go deeper on encapsulated fecal microbiota transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on encapsulated fecal microbiota transplantation.